Michael A Vogelbaum

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Update of stereotactic radiosurgery for brain tumors
    John H Suh
    Department of Radiation Oncology, Brain Tumor Institute, Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Curr Opin Neurol 17:681-6. 2004
  2. ncbi Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin
    Michael A Vogelbaum
    Brain Tumor Institute and Departments of Biostatistics, Neurosurgery, and Radiation Oncology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Neurosurg 104:907-12. 2006
  3. ncbi Convection-enhanced delivery of therapeutic agents into the brain
    Michael A Vogelbaum
    Department of Neurological Surgery, Cleveland Clinic, Cleveland, OH, USA
    Handb Clin Neurol 104:355-62. 2012
  4. ncbi Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results
    Michael A Vogelbaum
    Brain Tumor and Neuro Oncology Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Neurosurgery 61:1031-7; discussion 1037-8. 2007
  5. ncbi Resectable brain metastases
    Michael A Vogelbaum
    Brain Tumor Institute ND40, Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 24:1289-94. 2006
  6. ncbi Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review
    Michael A Vogelbaum
    Brain Tumor Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    J Neurooncol 83:97-109. 2007
  7. ncbi Convection enhanced delivery for the treatment of malignant gliomas: symposium review
    Michael A Vogelbaum
    Brain Tumor Institute, Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Neurooncol 73:57-69. 2005
  8. ncbi Stereotactic radiosurgical treatment of brain metastases to the choroid plexus
    Vitaly Siomin
    Department of Neurosurgery, Cleveland Clinic, Cleveland, OH, USA
    Int J Radiat Oncol Biol Phys 80:1134-42. 2011
  9. ncbi Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery
    Abigail L Stockham
    Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk T28, Cleveland, OH, 44195, USA
    J Neurooncol 109:149-58. 2012
  10. ncbi Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution
    Lewis A Rosenberg
    Department of Radiation Oncology, Cleveland Clinic Foundation, OH 44195, USA
    Int J Radiat Oncol Biol Phys 74:427-32. 2009

Detail Information

Publications71

  1. ncbi Update of stereotactic radiosurgery for brain tumors
    John H Suh
    Department of Radiation Oncology, Brain Tumor Institute, Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Curr Opin Neurol 17:681-6. 2004
    ..Future studies are needed to further improve outcomes, minimize toxicities and increase our understanding of this treatment modality...
  2. ncbi Local control of brain metastases by stereotactic radiosurgery in relation to dose to the tumor margin
    Michael A Vogelbaum
    Brain Tumor Institute and Departments of Biostatistics, Neurosurgery, and Radiation Oncology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Neurosurg 104:907-12. 2006
    ..The goal in this retrospective study was to determine whether differences in doses to the margins of brain metastases affect the ability of SRS to achieve local control...
  3. ncbi Convection-enhanced delivery of therapeutic agents into the brain
    Michael A Vogelbaum
    Department of Neurological Surgery, Cleveland Clinic, Cleveland, OH, USA
    Handb Clin Neurol 104:355-62. 2012
    ..New trials are being planned to investigate agents that can be coinfused with radiographic tracers, as well as novel catheters that avoid problems with backflow and potentially will provide more reliable drug distribution...
  4. ncbi Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results
    Michael A Vogelbaum
    Brain Tumor and Neuro Oncology Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Neurosurgery 61:1031-7; discussion 1037-8. 2007
    ....
  5. ncbi Resectable brain metastases
    Michael A Vogelbaum
    Brain Tumor Institute ND40, Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 24:1289-94. 2006
    ..As a result, overall survival is much more dependent on the status of the patient's systemic disease...
  6. ncbi Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review
    Michael A Vogelbaum
    Brain Tumor Institute, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    J Neurooncol 83:97-109. 2007
    ..Each speaker's presentation has been abstracted along with relevant references...
  7. ncbi Convection enhanced delivery for the treatment of malignant gliomas: symposium review
    Michael A Vogelbaum
    Brain Tumor Institute, Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Neurooncol 73:57-69. 2005
    ..Each speaker's talk has been abstracted and a list of relevant references has been compiled...
  8. ncbi Stereotactic radiosurgical treatment of brain metastases to the choroid plexus
    Vitaly Siomin
    Department of Neurosurgery, Cleveland Clinic, Cleveland, OH, USA
    Int J Radiat Oncol Biol Phys 80:1134-42. 2011
    ..Choroid plexus metastases (CPM) are uncommon lesions. Consequently, optimal management of CPM is uncertain. We summarize our experience with stereotactic radiosurgery (SRS) of CPM...
  9. ncbi Conventional MRI does not reliably distinguish radiation necrosis from tumor recurrence after stereotactic radiosurgery
    Abigail L Stockham
    Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Desk T28, Cleveland, OH, 44195, USA
    J Neurooncol 109:149-58. 2012
    ..Standard MRI techniques do not reliably discriminate between tumor progression and RN after treatment with SRS for brain metastases. Additional imaging modalities are warranted to aid in distinguishing between these diagnoses...
  10. ncbi Long-term experience with World Health Organization grade III (malignant) meningiomas at a single institution
    Lewis A Rosenberg
    Department of Radiation Oncology, Cleveland Clinic Foundation, OH 44195, USA
    Int J Radiat Oncol Biol Phys 74:427-32. 2009
    ..To evaluate the outcomes for patients with Grade III meningiomas as defined by the 2007 World Health Organization standards...
  11. ncbi Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
    David M Peereboom
    Brain Tumor and Neuro Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, Cleveland, OH 44195, USA
    J Neurooncol 98:93-9. 2010
    ..Erlotinib co administered with RT and temozolomide was not efficacious and had an unacceptable toxicity...
  12. ncbi Role of Gamma Knife surgery in patients with 5 or more brain metastases
    Alireza Mohammad Mohammadi
    The Rose Ella Burkhardt Brain Tumor and Neuro Oncology Center, Cleveland Clinic, Cleveland, Ohio, USA
    J Neurosurg 117:5-12. 2012
    ..The authors evaluated overall survival and factors predicting outcome in patients with ≥ 5 brain metastases who were treated with Gamma Knife surgery (GKS)...
  13. ncbi Gamma knife stereotactic radiosurgery for the management of incidentally-identified brain metastasis from non-small cell lung cancer
    Nicholas F Marko
    Department of Neurosurgery, Cleveland Clinic, Cleveland, OH, USA
    J Neurooncol 104:817-24. 2011
    ..Our findings suggest that SRS alone may be a viable therapeutic option for patients with incidentally-discovered NSCLC brain metastases...
  14. ncbi Treatment of five or more brain metastases with stereotactic radiosurgery
    Grant K Hunter
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA
    Int J Radiat Oncol Biol Phys 83:1394-8. 2012
    ..To examine the outcomes of patients with five or more brain metastases treated in a single session with stereotactic radiosurgery (SRS)...
  15. ncbi Relationship between HER2 status and prognosis in women with brain metastases from breast cancer
    Zhiyuan Xu
    Brain Tumor and Neuro Oncology Center, Cleveland Clinic, Cleveland, OH, USA
    Int J Radiat Oncol Biol Phys 82:e739-47. 2012
    ..To analyze factors affecting outcomes in breast cancer patients with brain metastases (BM) and characterize the role of HER2 status...
  16. ncbi Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme
    Aimee L Quan
    Department of Radiation Oncology, Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 63:695-703. 2005
    ..Further studies are needed to fully delineate the significance of this molecular marker in patients with GBM...
  17. ncbi Stereotactic radiosurgery for single brainstem metastases: the cleveland clinic experience
    Shlomo A Koyfman
    Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, OH, USA
    Int J Radiat Oncol Biol Phys 78:409-14. 2010
    ..To assess the imaging and clinical outcomes of patients with single brainstem metastases treated with stereotactic radiosurgery (SRS)...
  18. ncbi Gender, race, and survival: a study in non-small-cell lung cancer brain metastases patients utilizing the radiation therapy oncology group recursive partitioning analysis classification
    Gregory M M Videtic
    Department of Radiation Oncology, Taussig Cancer Institute, The Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 75:1141-7. 2009
    ....
  19. ncbi Stereotactic radiosurgical treatment of brain metastases in older patients
    Se Hyuk Kim
    The Brain Tumor and Neuro Oncology Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Cancer 113:834-40. 2008
    ..This study was designed to evaluate the therapeutic effect of stereotactic radiosurgery (SRS) in patients aged > or =75 years who presented with brain metastasis...
  20. ncbi The importance of the conformality, heterogeneity, and gradient indices in evaluating Gamma Knife radiosurgery treatment plans for intracranial meningiomas
    Ehsan H Balagamwala
    Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA
    Int J Radiat Oncol Biol Phys 83:1406-13. 2012
    ..To investigate the relationship between the conformality index (CIn), heterogeneity index (HIn), and gradient index (GIn) and the development of toxicity in patients treated with Gamma Knife radiosurgery (GKRS) for intracranial meningiomas...
  21. ncbi The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making
    Andrew A Kanner
    The Brain Tumor Institute, The Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Neurosurg 104:542-50. 2006
    ..The authors of further prospective studies may better determine the true value of the allelic loss of 1p and its implication for clinical decision making...
  22. ncbi Salvage stereotactic radiosurgery effectively treats recurrences from whole-brain radiation therapy
    Samuel T Chao
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer 113:2198-204. 2008
    ....
  23. ncbi RPA classification has prognostic significance for surgically resected single brain metastasis
    Rahul D Tendulkar
    Department of Radiation Oncology, Brain Tumor Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 66:810-7. 2006
    ..RPA class 1 patients have a very favorable prognosis with a median survival of 21.4 months...
  24. ncbi Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases
    Nicholas F Marko
    Department of Neurosurgery, The Cleveland Clinic, Cleveland, OH 44195, USA
    World Neurosurg 73:186-93; discussion e29. 2010
    ....
  25. ncbi Impact of preexisting tumor necrosis on the efficacy of stereotactic radiosurgery in the treatment of brain metastases in women with breast cancer
    Zhiyuan Xu
    Brain Tumor and Neuro Oncology Center, Department of Neurosurgery, Neurological Institute, Cleveland, Ohio, USA
    Cancer 118:1323-33. 2012
    ..Necrosis is a common feature of many brain tumors, including BM; however, the influence of tumor necrosis on treatment efficacy of SRS in women with breast cancer metastatic to the brain is unknown...
  26. ncbi Brain metastases
    Mark E Shaffrey
    Department of Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA
    Curr Probl Surg 41:665-741. 2004
  27. ncbi The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas
    Narendra Nathoo
    Department of Neurosurgery, The Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Neurooncol 81:167-74. 2007
    ..We report the use of (111)indium-octreotide brain scintigraphy (OBS) for the non-invasive differentiation of meningiomas from other cranial dural-based pathology...
  28. ncbi Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131
    Michael A Vogelbaum
    Cleveland Clinic, Brain Tumor and NeuroOncology Center, Cleveland, OH 44195, USA
    Neuro Oncol 11:167-75. 2009
    ..Future studies will need to prospectively stratify patients according to the presence of deletions of chromosomes 1p and 19q...
  29. ncbi Novel drug delivery strategies in neuro-oncology
    Dani S Bidros
    Department of Neurological Surgery, Brain Tumor and NeuroOncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Neurotherapeutics 6:539-46. 2009
    ..In this review, we describe the clinically available methods used to circumvent the blood brain barrier and summarize the results to date of ongoing and completed clinical trials...
  30. ncbi Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma
    Se Hyuk Kim
    The Brain Tumor and Neuro Oncology Center, Cleveland Clinic, Cleveland, OH 44195, USA
    Surg Neurol 69:641-6; discussion 646. 2008
    ..Prostate cancer metastatic to the brain is uncommon and has been associated historically with a poor prognosis. It has been suggested that SRS may be an effective treatment...
  31. ncbi S100beta as a predictor of brain metastases: brain versus cerebrovascular damage
    Michael A Vogelbaum
    Brain Tumor Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Cancer 104:817-24. 2005
    ....
  32. ncbi Posterior fossa metastases: risk of leptomeningeal disease when treated with stereotactic radiosurgery compared to surgery
    Vitaly E Siomin
    Department of Neurosurgery, Brain Tumor Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Neurooncol 67:115-21. 2004
    ..A prospective study directly comparing surgery and SRS and further evaluating the significance of LMD in PFM is warranted...
  33. ncbi Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas
    Manmeet S Ahluwalia
    Brain Tumor and Neuro Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Ave, R35, Cleveland, OH 44195, USA
    J Neurooncol 102:317-21. 2011
    ..The activity at the dose and schedule used in this study, however, was modest and the study did not meet its efficacy endpoint...
  34. ncbi Imaging characteristics of zinc sulfide shell, cadmium telluride core quantum dots
    Hamid Daneshvar
    Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Nanomedicine (Lond) 3:21-9. 2008
    ..Their electron-dense, metallic cores suggest utility in other clinical imaging modalities...
  35. ncbi Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions
    Mital Patel
    Neuro Oncology Outcomes, Neurological Institute, Cleveland Clinic, The Rose Ella Burkhardt Brain Tumor and Neuro Oncology Center, Cleveland, OH, USA
    Expert Opin Investig Drugs 21:1247-66. 2012
    ....
  36. ncbi Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases
    Susan Guo
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44113, USA
    Lung Cancer 77:389-93. 2012
    ..Using a large BM patient database, we assessed the impact of histologic subtypes on survival stratified by the GPA...
  37. ncbi Long-term outcomes of Gamma Knife radiosurgery in patients with vestibular schwannomas
    Erin S Murphy
    Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Neurosurg 114:432-40. 2011
    ..The authors sought to determine the long-term tumor control and side effects of Gamma Knife radiosurgery (GKRS) in patients with vestibular schwannomas (VS)...
  38. ncbi Five-year survivors of brain metastases: a single-institution report of 32 patients
    Samuel T Chao
    Department of Radiation Oncology, Brain Tumor Institute, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Int J Radiat Oncol Biol Phys 66:801-9. 2006
    ..CONCLUSIONS: For patients with good prognostic factors such as young age, good RPA characteristics and single metastasis, treatment with surgery or SRS offers the best chance for long-term survival...
  39. ncbi Management of brain metastases
    John H Suh
    Brain Tumor and Neuro Oncology Center, Department of Radiation Oncology, T28, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Neurol Neurosci Rep 9:223-30. 2009
    ..This review of the management of brain metastases focuses on whole brain radiation therapy, surgery, stereotactic radiosurgery, radiation sensitizers, and clinical trials...
  40. ncbi Prospective study of the short-term adverse effects of gamma knife radiosurgery
    Samuel T Chao
    Rose Ella Burkhardt Brain Tumor and Neuro Oncology Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Technol Cancer Res Treat 11:117-22. 2012
    ..This prospective study demonstrates that GK is well tolerated with few patients developing major acute effects. Many patients are able to return to work shortly after GK...
  41. ncbi A nomogram for individualized estimation of survival among patients with brain metastasis
    Jill S Barnholtz-Sloan
    Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106 5065, USA
    Neuro Oncol 14:910-8. 2012
    ..An estimated 24%-45% of patients with cancer develop brain metastases. Individualized estimation of survival for patients with brain metastasis could be useful for counseling patients on clinical outcomes and prognosis...
  42. ncbi Histidine-rich glycoprotein modulates the anti-angiogenic effects of vasculostatin
    Philip A Klenotic
    Department of Cell Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
    Am J Pathol 176:2039-50. 2010
    ..These data help define a novel angiogenic axis that could be exploited for the treatment of human cancers and other diseases where excess angiogenesis occurs...
  43. ncbi Use of the Radiation Therapy Oncology Group recursive partitioning analysis classification system and predictors of survival in 19 women with brain metastases from ovarian carcinoma
    Philip G Chen
    Department of Radiation Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Cancer 104:2174-80. 2005
    ..The number of metastatic intracranial lesions should be included when determining the prognosis...
  44. ncbi Future of convection-enhanced delivery in the treatment of brain tumors
    Dani S Bidros
    Brain Tumor and NeuroOncology Center, Department of Neurological Surgery, Neurological Institute, Cleveland Clinic, OH 44195, USA
    Future Oncol 6:117-25. 2010
    ..In this review, we summarize the recent past of the clinical trials utilizing CED and discuss emerging technologies that will shape future CED trials...
  45. ncbi Posterior fossa metastases: aggressive treatment improves survival
    Andrew A Kanner
    Department of Neurosurgery, Brain Tumor Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Stereotact Funct Neurosurg 81:18-23. 2003
    ..CONCLUSIONS: Survival of patients with cerebellar brain metastasis is comparable to that of patients with supratentorial brain metastasis using RPA classification. Aggressive multimodality therapy has a favorable impact on survival...
  46. ncbi Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group
    Michael A Vogelbaum
    Brain Tumor and Neuro Oncology Center, Department of Neurosurgery, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Neurosurgery 70:234-43; discussion 243-4. 2012
    ..The RANO group identified knowledge gaps relating to the definitions of tumor response and progression after the use of surgical or surgically based treatments...
  47. ncbi Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2
    Shaik Ohidar Rahaman
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Ohio 44195, USA
    Cancer Res 65:2956-63. 2005
    ..These results indicate that IL-4/IL-13 receptor-mediated Stat3 signaling may contribute to the pathogenesis of GBM cells by modulating the expression of the Bcl-2 family of antiapoptotic proteins...
  48. ncbi Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells
    Shaik Ohidar Rahaman
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio, OH 44195, USA
    Oncogene 21:8404-13. 2002
    ..Therefore, targeting Stat3 signaling may provide a potential therapeutic intervention for GBM...
  49. ncbi p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation
    Sreejith P Panicker
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Ohio 44195, USA
    Oncotarget 1:289-303. 2010
    ..Because invasion is a major cause of GBM morbidity, differentiation therapy may improve the clinical outcome...
  50. ncbi Modern treatment of cerebral metastases: Integrated Medical Learning(SM) at CNS 2007
    Michael A Vogelbaum
    Brain Tumor and Neuro Oncology Center, The Cleveland Clinic Foundation, Cleveland, OH, USA
    J Neurooncol 93:89-105. 2009
    ....
  51. ncbi In touch with robotics: neurosurgery for the future
    Narendra Nathoo
    Brain Tumor Institute and Department of Neurosurgery, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Neurosurgery 56:421-33; discussion 421-33. 2005
    ..This article reviews the role of robotic technology in the context of neurosurgery...
  52. ncbi Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors
    Vitaly Siomin
    Department of Neurosurgery, The Cleveland Clinic Brain Tumor Institute, 9500 Euclid Avenue, ND-40, Cleveland, OH 44195, USA
    J Neurooncol 74:211-5. 2005
    ..Additional larger prospective studies with appropriate patient stratification culminating in development of neurosurgical guidelines on AED prophylaxis in brain tumor patients is warranted...
  53. ncbi Cyclooxygenase-2 in oligodendroglial neoplasms
    Elias A Castilla
    Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Cancer 98:1465-72. 2003
    ..Tumors with expression of COX-2 by immunohistochemistry may, in theory, benefit from treatment with therapeutic agents that inhibit COX-2...
  54. ncbi Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
    Baisakhi Raychaudhuri
    Brain Tumor and Neuro Oncology Center, Neurological Institute, Cleveland, OH, USA
    Neuro Oncol 13:591-9. 2011
    ..Increased plasma levels of arginase and G-CSF may relate to MDSC suppressor function and MDSC expansion, respectively, in patients with glioma...
  55. ncbi Brain metastases from esophageal cancer: a phenomenon of adjuvant therapy?
    Thomas W Rice
    The Center for Swallowing and Esophageal Disorders, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Ann Thorac Surg 82:2042-9, 2049.e1-2. 2006
    ..Therefore, we determined (1) incidence and prevalence of, risk factors for, and survival after development of brain metastases following esophagectomy for esophageal cancer, and (2) their association with adjuvant therapy...
  56. ncbi Intracranial collision tumor mimicking an octreotide-SPECT positive and FDG-PET negative meningioma
    Ali Chahlavi
    Department of Neurosurgery, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Neurosci 12:720-3. 2005
    ..A high degree of suspicion of intracranial metastasis should be maintained for patients who have known systemic cancer and are found incidentally to have a dural-based mass lesion...
  57. ncbi Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions
    Andrew A Kanner
    Brain Tumor Institute, The Cleveland Clinic, Ohio 44195, USA
    Cancer 97:2806-13. 2003
    ..Larger prospective studies may better determine the true specificity of S100beta as a marker for BBB function and as an early detection or follow-up marker of brain tumors...
  58. ncbi Silencing IL-13Rα2 promotes glioblastoma cell death via endogenous signaling
    Linda C Hsi
    Department of Cell Biology, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio 44195, USA
    Mol Cancer Ther 10:1149-60. 2011
    ..Identifying a mechanistic pathway that can be targeted for pharmacologic intervention will have applied implications to developing novel and effective treatments of GBM...
  59. ncbi Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype
    Baisakhi Raychaudhuri
    Brain Tumor Institute and Taussig Cancer Center, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Neurooncol 85:39-47. 2007
    ..Interruption of this aberrant NF-kappaB activity may help reduce the spread of this infiltrative tumor...
  60. ncbi Opportunities for clinical research in meningioma
    Michael A Vogelbaum
    Brain Tumor and NeuroOncology Center, Cleveland Clinic, Cleveland, OH 44195, USA
    J Neurooncol 99:417-22. 2010
    ..Finally, we discuss ongoing efforts to develop new trials to more definitively address important therapeutic questions...
  61. ncbi IL-8 is a mediator of NF-κB induced invasion by gliomas
    Baisakhi Raychaudhuri
    Brain Tumor and Neuro Oncology Center, Neurological Institute, Cleveland Clinic, 9500 Euclid Avenue ND40, Cleveland, OH 44195, USA
    J Neurooncol 101:227-35. 2011
    ..Our data indicate that IL-8 is necessary but not solely responsible for glioma cell invasion and mediates its effect in an autocrine manner...
  62. ncbi Mapping prosody: correlation of functional magnetic resonance imaging with intraoperative electrocorticography recordings in a patient with a right-sided temporooccipital glioma. Case illustration
    Narendra Nathoo
    Brain Tumor Institute, The Taussig Cancer Center, Cleveland, Ohio 44195, USA
    J Neurosurg 103:930. 2005
  63. ncbi PTPmu suppresses glioma cell migration and dispersal
    Adam M Burgoyne
    Department of Molecular Biology and Microbiology, School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
    Neuro Oncol 11:767-78. 2009
    ..Together, these data suggest that loss of PTPmu in human GBMs contributes to tumor cell migration and dispersal, implicating loss of PTPmu in glioma progression...
  64. ncbi Quantum dots are phagocytized by macrophages and colocalize with experimental gliomas
    Heather Jackson
    Brain Tumor Institute, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Neurosurgery 60:524-9; discussion 529-30. 2007
    ..This feature may allow optical nanoparticles, such as quantum dots, to colocalize with brain tumors and serve as an optical aid in the surgical resection or biopsy of brain tumors...
  65. ncbi Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas
    Narendra Nathoo
    Center for Translational Therapeutics, Brain Tumor Institute, Cleveland Clinic Foundation, Ohio 44195, USA
    Neurosurgery 54:1480-8; discussion 1488-9. 2004
    ..The use of anti-EGFR therapies against malignant brain tumors, although in its infancy, promises to yield exciting results as these new drugs probably will enhance the usefulness of existing therapies...
  66. ncbi Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme
    Richard A Prayson
    Brain Tumor Center and the Department of Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Ann Diagn Pathol 6:148-53. 2002
    ..These findings are significant in that therapeutic agents, which inhibit COX-2, are currently available and may play a role in the management of glioblastoma multiforme...
  67. ncbi IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells
    Shaik Ohidar Rahaman
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Cancer Res 62:1103-9. 2002
    ..Thus, IL-13R(alpha)2 acts as an inhibitor of IL-4-dependent signal transduction pathways via a novel mechanism that is independent of ligand binding...
  68. ncbi Multidisciplinary management of colorectal brain metastases: a retrospective study
    Tim J Kruser
    Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
    Cancer 113:158-65. 2008
    ..The incidence of brain metastases (BM) from colorectal cancer (CRC) is increasing, and the management of this previously rare complication at a single institution is reported...
  69. ncbi Intracranial navigation by using low-field intraoperative magnetic resonance imaging: preliminary experience
    Andrew A Kanner
    Department of Neurosurgery, Tel Aviv Sourasky Medical Center, Sackler Faculty of Mmedicine, Tel Aviv University, Israel
    J Neurosurg 97:1115-24. 2002
    ..Standard neurosurgical drills, microscopes, and other equipment can be used safely in conjunction with this iMR imaging system...
  70. ncbi Results of a phase II trial of the GliaSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases
    Lisa R Rogers
    Department of Neurology and Neurosurgery, Henry Ford Hospital, Detroit, Michigan 48109 0316, USA
    J Neurosurg 105:375-84. 2006
    ..The primary end point of the study was local tumor control. The secondary end points included patient survival, distant brain recurrence, quality of life, and treatment toxicity...
  71. ncbi Caspase-9 transduction overrides the resistance mechanism against p53-mediated apoptosis in U87MG glioma cells
    Michael A Vogelbaum
    Neurosurgery 50:673-4. 2002